Patient Diversity and Beyond: Tapping the Potential of the Asia Pacific for Clinical Trials

In the last 10 years, APAC has become a hotspot for clinical trials: the region contributed almost 50% of new clinical trial activity globally in 2021 and looks poised to overtake ROW trials in 2022. There has been a meaningful shift in APAC trials towards a greater proportion of early phase trials conducted. The region has also taken the lead in cell and gene clinical trials, accounting for the largest share of new trials during the first half of 2022. This trend can be attributed to the development of trial infrastructure and capabilities, including the growth of clinical research networks, as well as the growth of indigenous biotech and pharma companies from the region, and the presence of a diverse population base accounting for more than 40% of the global population. This session brings together regional experts from industry and clinical trial institutions to discuss the current state of play, and more importantly, future developments and perspectives towards successful clinical trial strategies in APAC.